Richard E. Uihlein - 16 Jan 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role: Director, 10%+ Owner
Signature: Jack W. Callicutt, by power of attorney
Issuer symbol: GALT
Transactions as of: 16 Jan 2026
Net transactions value: +$40,000
Form type: 4
Filing time: 21 Jan 2026, 16:44:18 UTC
Previous filing: 27 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Uihlein Richard E	Director, 10%+ Owner	4960 PEACHTREE INDUSTRIAL BLVD, SUITE 240, NORCROSS	Jack W. Callicutt, by power of attorney	21 Jan 2026	0001694903

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GALT	Common Stock	Award	$40,000	+13,158	+0.13%	$3.04	10,332,676	16 Jan 2026	Direct	F3
holding	GALT	Common Stock						27,710	16 Jan 2026	By Ed Uihlein Family Foundation	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GALT	Stock option (right to buy)	Award	$0	+60,000		$0.000000	60,000	16 Jan 2026	Common Stock	60,000	$3.04	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2	The options vest 100% on December 31, 2026.
F3	These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026.
F4	The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.